TUZISTRA XR Drug Patent Profile

Which patents cover Tuzistra Xr, and what generic alternatives are available?

Tuzistra Xr is a drug marketed by Tris Pharma Inc and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in TUZISTRA XR is chlorpheniramine polistirex; codeine polistirex. There are twenty-nine drug master file entries for this compound. Additional details are available on the chlorpheniramine polistirex; codeine polistirex profile page.

DrugPatentWatch^® Generic Entry Outlook for Tuzistra Xr

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 15, 2027. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TUZISTRA XR

International Patents:	21
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TUZISTRA XR

US Patents and Regulatory Information for TUZISTRA XR

TUZISTRA XR is protected by two US patents.

This potential generic entry date is based on patent 8,790,700.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tris Pharma Inc	TUZISTRA XR	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	207768-001	Apr 30, 2015		DISCN	Yes	No	8,790,700		Y
Tris Pharma Inc	TUZISTRA XR	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	207768-001	Apr 30, 2015		DISCN	Yes	No	8,062,667		Y

International Patents for TUZISTRA XR

When does loss-of-exclusivity occur for TUZISTRA XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Brazil

European Patent Office

Israel

Japan

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TUZISTRA XR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2428205	Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes)
Japan	2009530298
China	102488652	Modified release formulations containing drug-ion exchange resin complexes
Denmark	2018160
Brazil	PI0709606	suspensão líquida administrável oralmente com características de liberação modificada
European Patent Office	2018160	FORMULATIONS A LIBERATION MODIFIEE CONTENANT DES COMPLEXES MEDICAMENT - RESINE ECHANGEUSE D'IONS (MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES)

Investment Scenario and Fundamentals Analysis for TUZISTRA XR

Last updated: February 24, 2026

What is TUZISTRA XR?

TUZISTRA XR (tucatinib) is a kinase inhibitor targeting HER2-positive cancers, primarily used in breast cancer therapy. It is administered orally in extended-release formulations. Approved by the FDA in April 2020, TUZISTRA XR is indicated for adult patients with HER2-positive metastatic or unresectable breast cancer who have received prior therapies.

Market Overview

Approved Indications and Commercial Potential

• Primary Use: HER2-positive metastatic breast cancer
• Market Penetration: Focuses on a niche within the breast cancer segment
• Competitors: Trastuzumab deruxtecan, trastuzumab emtansine, neratinib
• Sales Figures: Estimated U.S. sales of TUZISTRA XR reached approximately $200 million in 2022 (Evaluate Pharma, 2023).

Geographic Expansion Opportunities

• Regulatory approvals in Europe and Asia pending.
• Potential for expanding into earlier lines of therapy pending trial results.

Clinical and Regulatory Fundamentals

Clinical Trial Data

• Phase III HER2CLIMB trial: Demonstrated a 46% reduction in disease progression risk compared to placebo.
• Overall Survival (OS): Median OS improved in combination with trastuzumab and capecitabine.

FDA and Global Approvals

• FDA: Approved in April 2020 for refractory HER2-positive metastatic breast cancer.
• EMA: Submission submitted; approval expected within the next year.
• Other regulators: Approval timelines depend on local review processes.

Pharmacokinetics and Dosing

• Extended-release tablet taken once daily.
• Supports adherence and improves patient compliance.
• Side-effect profile includes diarrhea, nausea, and hand-foot syndrome.

Financial and Investment Considerations

Revenue and Growth Trajectory

• Sales 2022: ~$200 million in the U.S.
• Growth Drivers: Increasing adoption, expanding indications, combination therapies.
• Forecasted CAGR: 20-25% over the next five years, driven by increased market penetration.

Patent and Patent Life

• Patent Expiry: Expected in 2035.
• Patent Portfolio: Includes composition of matter, formulation, and method of use protections.

Manufacturing and Supply Chain

• Approved manufacturing facilities meet global standards (cGMP).
• Supply chain risks are mitigated through diversified sourcing.

Competitive Positioning

Competitor	Mechanism	Market Share (2022)	Differentiation
TUZISTRA XR	HER2 tyrosine kinase inhib	60% of HER2 oral drugs	Once daily dosing, favorable side-effect profile
Neratinib	HER2/EGFR inhibitor	25%	Broader kinase inhibition
Trastuzumab deruxtecan	Antibody-drug conjugate	10%	Potent, for refractory cases

Key Risks and Challenges

• Market Competition: Several drugs target HER2-positive breast cancer but few have the same oral, once-daily profile.
• Clinical Efficacy: Long-term data needed to confirm survival benefits.
• Regulatory Risks: Pending approvals in key regions could delay revenue.

Investment Outlook

TUZISTRA XR holds a position in a niche but growing segment of HER2-positive breast cancer therapies. The drug’s established efficacy, favorable dosing, and patent life support its valuation. The primary value drivers include increasing adoption, new indications, and potential market expansion. Risks revolve around competition, regulatory delays, and long-term survival data.

Key Takeaways

• TUZISTRA XR is a targeted oral therapy with FDA approval for refractory HER2-positive metastatic breast cancer.
• The drug’s sales are on an upward trajectory, supported by clinical efficacy and convenient dosing.
• Market opportunities exist for expansion into earlier lines of therapy and international markets.
• Patent protection extends to 2035, providing patent exclusivity.
• Competition, long-term data, and regulatory approvals in other regions remain critical factors.

FAQs

1. What is the primary clinical benefit of TUZISTRA XR?
   It reduces disease progression risk in HER2-positive metastatic breast cancer patients who have received prior therapies.

2. When is TUZISTRA XR expected to face patent expiry?
   Patent protection is expected to last until 2035.

3. What are the main competitors of TUZISTRA XR?
   Neratinib and trastuzumab deruxtecan are key competitors, with differing mechanisms and administration routes.

4. What are the major risks associated with investing in TUZISTRA XR?
   Risks include market competition, potential delays in international regulatory approvals, and the need for long-term survival data.

5. What are the growth prospects for TUZISTRA XR?
   The drug is projected to grow at a CAGR of 20-25% over the next five years, driven by increased adoption and expanding indications.

---

References

1. Evaluate Pharma. (2023). Global sales data for TUZISTRA XR.
2. U.S. Food and Drug Administration. (2020). FDA approval letter for tucatinib.
3. HER2CLIMB trial publication. (2021). New England Journal of Medicine.